DÄ internationalArchive18/2020Bleeding during oral anticoagulation

Editorial

Bleeding during oral anticoagulation

A comparison between vitamin K antagonists and direct oral anticoagulants

Dtsch Arztebl Int 2020; 117: 311. DOI: 10.3238/arztebl.2020.0311

Pötzsch, B

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Institut für Experimentelle Hämatologie und Transfusionsmedizin, Universitätsklinikum Bonn: Prof. Dr. med. Bernd Pötzsch
1.Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51 CrossRef MEDLINE
2. Patel MR, Mahaffey KW, Garg J, et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91 CrossRef MEDLINE
3. Granger CB, Alexander JH, McMurray JJ, et al.: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 365: 981–92 CrossRef MEDLINE
4. Giugliano RP, Ruff CT, Braunwald E, et al.: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–104 CrossRef MEDLINE
5.Ruff CT, Giugliano RP, Braunwald E, et al.: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet 2014; 383: 955–62 CrossRef
6. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893–962 CrossRef MEDLINE
7.Lindhoff-Last E, Herrmann E, Lindau S, et al.: Severe hemorrhage associated with oral anticoagulants—a prospective observational study of the clinical course during treatment with vitamin K antagonists or direct oral anticoagulants. Dtsch Arztebl Int 2020; 117: 312–9 VOLLTEXT